Abstract:Background/Aims: PITX1 has been identified as a potential tumor-suppressor gene in several malignant tumors. The molecular mechanism underlying PITX1, particularly its function as a transcription factor regulating gene expression during tumorigenesis, is still poorly understood. Methods: The expression level and location of PITX1 were determined by quantitative reverse transcription PCR (qRT-PCR) and immunohistochemical staining in gastric cancer (GC). The effect of PITX1 on the GC cell proliferation and tumorigenesis was analyzed in vitro and in vivo. To explore how PITX1 suppresses cell proliferation, we used PITX1-ChIP-sequencing to measure genome-wide binding sites of PITX1 and assessed global function associations based on its putative target genes. ChIP-PCR, electrophoretic mobility shift assay, and promoter reporter assays examined whether PITX1 bound to PDCD5 and regulated its expression. The function of PDCD5 in GC cell apoptosis was further examined in vitro and in vivo. The relationship between the PITX1 protein level and GC patient prognosis was evaluated by the Kaplan-Meier estimator. Meanwhile, the expression level of miR-19a-3p, which is related to PITX1, was also detected by luciferase reporter assay, qRT-PCR, and western blotting. Results: The expression level of PITX1 was decreased in GC tissues and cell lines. Elevated PITX1 expression significantly suppressed the cell proliferation of GC cells and tumorigenesis in vitro and in vivo. PITX1 knockdown blocked its inhibition of GC cell proliferation. PITX1 bound to whole genome-wide sites, with these targets enriched on genes with functions mainly related to cell growth and apoptosis. PITX1 bound to PDCD5, an apoptosis-related gene, during tumorigenesis, and cis-regulated PDCD5 expression. Increased PDCD5 expression in GC cells not only induced GC cell apoptosis, but also suppressed GC cell growth in vitro and in vivo. Moreover, PITX1 expression was regulated by miR-19a-3p. More importantly, a decreased level of PITX1 protein was correlated with poor GC patient prognosis. Conclusion: Decreased expression of PITX1 predicts shorter overall survival in GC patients. As a transcriptional activator, PITX1 regulates apoptosis-related genes, including PDCD5, during gastric carcinogenesis. These data indicate PDCD5 to be a novel and feasible therapeutic target for GC.

Expression of Programmed Cell Death 5 Gene Involves in Regulation of Apoptosis in Gastric Tumor Cells

The Clinical Significance of Reduced Programmed Cell Death 5 Expression in Human Gastrointestinal Stromal Tumors.

Transfection of PDCD5 Effect on the Biological Behavior of Tumor Cells and Sensitized Gastric Cancer Cells to Cisplatin-Induced Apoptosis

Expression of Programmed Cell Death Factor 4 and Its Pathological Significance in Gastric Cancer

Cellular functions of programmed cell death 5.

Expression of programmed cell death 4 (PDCD4) related to tumor differentiation in human cancers of digestive system

Protocadherin 17 Acts As a Tumour Suppressor Inducing Tumour Cell Apoptosis and Autophagy, and is Frequently Methylated in Gastric and Colorectal Cancers

PDCD5 (programmed Cell Death 5)

The roles of serum PDCD5 in circulating CD133 positive cells of the patients with gastric cancer

Programmed Cell Death 4 (PDCD4) Mediates the Sensitivity of Gastric Cancer Cells to TRAIL-induced Apoptosis by Down-Regulation of FLIP Expression.

Programmed Cell Death 4 (PDCD4) Enhances the Sensitivity of Gastric Cancer Cells to TRAIL-Induced Apoptosis by Inhibiting the PI3K/Akt Signaling Pathway

CXXC4 activates apoptosis through up-regulating GDF15 in gastric cancer.

Low programmed cell death 5 expression is a prognostic factor in ovarian cancer.

[High Expression of Death-Associated Protein 5 Promotes Glucose Metabolism in Gastric Cancer Cells and Correlates with Poor Survival Outcomes].

Transgenic human programmed cell death 5 expression in mice suppresses skin cancer development by enhancing apoptosis

Downregulated PITX1 Modulated by MiR-19a-3p Promotes Cell Malignancy and Predicts a Poor Prognosis of Gastric Cancer by Affecting Transcriptionally Activated PDCD5

Programmed cell death 5 enhance inhibitory effect of cisplatin on growth of colorectal carcinoma cells in vivo

DGCR5 is Activated by PAX5 and Promotes Pancreatic Cancer Via Targeting Mir-3163/Top2a and Activating Wnt/β-Catenin Pathway

Pan-cancer Analysis of Oncogenic Role of Programmed Cell Death 2 Like (PDCD2L) and Validation in Colorectal Cancer

Reduced Expression of PDCD5 is Associated with High-Grade Astrocytic Gliomas.

Clinical significance of decreased programmed cell death 4 expression in patients with giant cell tumors of the bone.